keyword
MENU ▼
Read by QxMD icon Read
search

Acute GVHD

keyword
https://www.readbyqxmd.com/read/29779322/-impact-of-mycophenolate-mofetil-prophylaxis-duration-on-acute-graft-versus-host-disease-after-haploidentical-stem-cell-transplantation
#1
Y Q Sun, X J Huang, L P Xu, X H Zhang, C H Yan, K Y Liu, Y Wang
Objective: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using 'Beijing Protocol'. Methods: Adult patients (≥14 years) received haplo-HSCT in Peking University Institute of Hematology from Sep, 2016 to Mar, 2017 were retrospectively reviewed if they fulfilled the criterias: ①diagnosed with hematological maligancies; ②standard-risk status at haplo-HSCT. A total of 237 patients [including 102 patients with long MMF duration (defined as started on day -9 with 100 mg/d, adjusted to 500 mg/d from day +30 and discontinued on day +45 to +60 or occurrence of CMV/EBV reactivation or late-onset hemorrhagic cytitis), and 135 patients with short MMF duration (defined as started on day -9 with 500 mg/d and discontinued on the day achieved neutrophil engraftment)] were reviewed...
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29778715/photopheresis-of-a-less-than-10-kg-child-with-acute-graft-versus-host-disease-accompanied-with-hyperbilirubinemia-a-case-report
#2
REVIEW
Ashraf Malek Mohammadi, Amir Hossein Norooznezhad, Jerard Seghatchian, Mohsen Nikbakht, Farhad Heshmati, Saeed Mohammadi, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Hematopoietic stem cell transplantation is a curative treatment for many hematologic malignancies with its most important side effect being graft-versus-host disease (GVHD). Herein, we present a 3.5 year-old male with weight of 9.8 kg with acute GVHD (grade IV gastrointestinal and cutaneous) who did not respond to the first line therapies (corticosteroids). Thus, the patient was a candidate for extracorporeal photochemotherapy (ECP). Due to the hyperbilirubinemia, two sessions of ECP every week as well as one session of plasmapheresis 24 h before each ECP session were performed (Spectra™ Optia® apheresis system)...
May 9, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29770447/effectiveness-of-immunoglobulin-prophylaxis-in-reducing-clinical-complications-of-hematopoietic-stem-cell-transplantation-a-systematic-review-and-meta-analysis
#3
REVIEW
Hilalion Ahn, Jason Tay, Beverley Shea, Brian Hutton, Risa Shorr, Greg A Knoll, Donald William Cameron, Juthaporn Cowan
BACKGROUND: Prophylactic immunoglobulin has been used with varying efficacy to reduce complications in hematopoietic stem cell transplant recipients. STUDY DESIGN AND METHODS: A systematic review and meta-analysis was conducted of randomized controlled trials that assessed clinical outcomes (overall survival, transplant-related mortality, graft-versus-host disease [GVHD], veno-occlusive disease [VOD], interstitial pneumonitis, disease relapse, cytomegalovirus [CMV] infection and disease, non-CMV infection) of immunoglobulin prophylaxis versus placebo in hematopoietic stem cell transplant recipients...
May 16, 2018: Transfusion
https://www.readbyqxmd.com/read/29769208/infusion-of-alloanergized-donor-lymphocytes-after-cd34-selected-haploidentical-myeloablative-hematopoietic-stem-cell-transplantation
#4
Jeff K Davies, Lisa L Brennan, John Wingard, Christopher R Cogle, Neena Kapoor, Ami J Shah, Bimalangshu R Dey, Thomas R Spitzer, Marcos De Lima, Laurence Jn Cooper, Peter Thall, Richard E Champlin, Lee M Nadler, Eva C Guinan
PURPOSE: Allogeneic haematopoietic stem-cell transplantation (HSCT) is a curative treatment for many haematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) and delayed immune reconstitution. Alloanergization of donor T-cells is a simple approach to rebuild immunity whilst limiting GvHD after haploidentical HSCT but the optimal T-cell dose and impact on immune reconstitution remain unknown.  Experimental Design: We performed a multicentre Phase 1 trial of alloanergized donor lymphocyte infusion (aDLI) after CD34-selected myeloablative haploidentical HSCT...
May 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29763906/the-therapeutic-effect-of-icam-1-overexpressing-mesenchymal-stem-cells-on-acute-graft-versus-host-disease
#5
Bo Tang, Xue Li, Yuanlin Liu, Xiuhui Chen, Ximei Li, Yanan Chu, Heng Zhu, Weijiang Liu, Fenfen Xu, Fan Zhou, Yi Zhang
BACKGROUND/AIMS: Mesenchymal stem cells (MSCs) do not readily migrate to appropriate sites, and this creates a major obstacle for their use in the treatment of graft-versus-host disease (GVHD). Intercellular adhesion molecule-1 (ICAM-1) can guide the homing of various immune cells to the proper anatomical location within secondary lymphoid organs (SLOs), which are the major niches for generating immune responses or tolerance. MSCs rarely migrate to SLOs after intravenous infusion, and are constitutively low expression of ICAM-1...
May 7, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29760162/unrelated-cord-blood-transplantation-in-patients-with-acquired-refractory-aplastic-anemia-a-nationwide-phase-ii-study
#6
Regis Peffault de Latour, Sylvie Chevret, Charlotte Jubert, Anne Sirvent, Claire Galambrun, Annalisa Ruggeri, Virginie Gandemer, Jérôme Cornillon, Fanny Rialland, Jean-Hugues H Dalle, Edouard Forcade, Benedicte Bruno, Catherine Paillard, Pierre S Rorlich, Alexandra Salmon, Sabine Fürst, Flore Sicre de Fontbrune, Marie Therese Rubio, Jacques-Olivier Bay, Mohamad Mohty, Jerome Larghero, Eliane Gluckman, Gerard Socié
Outcomes remain poor for patients with refractory severe aplastic anemia (SAA). Alternative donor transplantation may be considered, but results from previous studies have not been encouraging. We conducted a prospective nationwide phase II study to assess the efficacy and safety of unrelated cord blood transplantation (CBT) in patients with refractory SAA (APCORD protocol, NCT 01343953). To demonstrate a significant difference in one-year survival from 20% (null hypothesis) to 50% (alternative hypothesis), we needed to include 25 transplanted patients...
May 14, 2018: Blood
https://www.readbyqxmd.com/read/29755481/-phage-transplantation-in-allotransplantation-possible-treatment-in-graft-versus-host-disease
#7
Andrzej Górski, Ewa Jończyk-Matysiak, Ryszard Międzybrodzki, Beata Weber-Dąbrowska, Jan Borysowski
Graft-versus-host disease, both acute and chronic (aGvHD, cGvHD) remains a major complication in patients undergoing hematopoietic cell transplantation (HCT) and a significant therapeutic challenge, as many patients do not respond adequately to presently available therapy. Increasing antimicrobial resistance has greatly revived interest in using bacterial viruses (phages) to combat antibiotic-resistant bacteria. In recent years, evidence has accumulated indicating that phages also have anti-inflammatory and immunomodulatory activities...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29753162/steroid-s-deleterious-effect-on-cmv-infection-rate-post-allo-sct-depends-on-pre-transplant-cmv-serostatus-of-donors-and-recipients
#8
María Suárez-Lledó, Núria Martínez-Cibrián, Gonzalo Gutiérrez-García, Veselka Dimova-Svetoslavova, Ma Angeles Marcos, Beatriz Martín-Antonio, Alejandra Martínez-Trillos, Neus Villamor, Laura Rosiñol, Carmen Martínez, Francesc Fernández-Avilés, Carolina García-Vidal, Álvaro Urbano-Ispizua, Montserrat Rovira
This study examined the impact of prednisone (PDN) on CMV infection after allogeneic stem cell transplantation (allo-SCT) according to donor (D) and recipient (R) CMV serostatus. Seventy-five patients underwent allo-SCT from June 2010 to July 2012. The risk of CMV infection according to D and R serostatus was defined as follows: high risk (HR) (D-/R+), intermediate risk (IR) (D+/R+ and D+/R-) and low risk (LR) (D-/R-). Forty-five patients (60%) developed CMV infection and forty-six patients (61%) received steroids (PDN ≥ 1 mg/kg/day) to treat acute Graft versus host disease (GvHD)...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753158/melphalan-based-reduced-intensity-conditioning-is-associated-with-favorable-disease-control-and-acceptable-toxicities-in-patients-older-than-70-with-hematologic-malignancies-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#9
Monzr M Al Malki, Nitya Nathwani, Dongyun Yang, Saro Armenian, Sanjeet Dadwal, Jaroslava Salman, Sally Mokhtari, Thai Cao, Karamjeet Sandhu, Michelle Rouse, Matthew Mei, Haris Ali, Pablo Parker, Joseph Alvarnas, Eileen Smith, Margaret O Donnell, Guido Marcucci, David Snyder, Auayporn Nademanee, Stephen J Forman, Anthony Stein, Ryotaro Nakamura
Allogeneic hematopoietic stem cell transplantation (AlloHCT) is offered increasingly to elderly patients with hematologic malignancies. However, outcome data in those who are 70 years or older are limited, and no standard conditioning regimen has been established for this population. In this retrospective study, we evaluated the outcome of 53 consecutive patients aged 70 years and older who underwent AlloHCT with melphalan (Mel)-based reduced-intensity conditioning (RIC) at City of Hope. Engraftment was prompt, with median time to neutrophil engraftment of 15 days...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753157/treosulfan-fludarabine-and-low-dose-total-body-irradiation-for-children-and-young-adults-with-acute-myeloid-leukemia-or-myelodysplastic-syndrome-undergoing-allogeneic-hematopoietic-cell-transplantation-a-prospective-phase-ii-trial-of-the-pediatric-blood-and
#10
Eneida R Nemecek, Ralf A Hilger, Alexia Adams, Bronwen E Shaw, Deidre Kiefer, Jennifer Le-Rademacher, John E Levine, Gregory Yanik, Wing Leung, Julie-An Talano, Paul Haut, David Delgado, Neena Kapoor, Aleksandra Petrovic, Roberta Adams, Rabi Hanna, Hemalatha Rangarajan, Jignesh Dalal, Joseph Chewning, Michael R Verneris, Stacy Epstein, Lauri Burroughs, Evelio D Perez-Albuerne, Michael A Pulsipher, Colleen Delaney
This multicenter study evaluated a treosulfan-based regimen in children and young adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). Forty patients with median age 11 years (1-19) underwent allogeneic HCT for AML in first (n=18), second (n=11), third or greater remission (n=3); or MDS (n=8) using bone marrow (n=25), peripheral blood stem cells (n=5) or cord blood (n=9). The regimen consisted of body surface area (BSA)-based treosulfan 10 g/m2 /day (BSA ≤ 0...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29747286/-anti-cd-25-monoclonal-antibody-as-a-salvage-therapy-for-steroid-refractory-acute-graft-versus-host-disease-in-80-patients-receiving-allogeneic-hematopoietic-stem-cell-transplantation
#11
T Tao, S L Xue, F Chen, Y Xu, X Ma, M Miao, X W Tang, D P Wu
Objective: To investigate the efficacy of anti-CD(25) monoclonal antibody for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Methods: A total of 80 patients with SR-aGVHD from January 1st 2012 to December 31st 20l6 were enrolled in this study. Acute GVHD were classified as classic aGVHD ( n= 72) and late-onset aGVHD ( n= 8). Anti-CD(25) monoclonal antibodys (mAb) were administrated on days 1, 4, 8, 15, and 22. The efficacy of anti-CD(25) mAb was evaluated at day 28 after the initial treatment...
May 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29745014/posttransplant-cyclophosphamide-for-haploidentical-stem-cell-transplantation-in-children-with-wiskott-aldrich-syndrome
#12
Yan Yue, Xiaodong Shi, Zeliang Song, Jiayue Qin, Junhui Li, Shunqiao Feng, Rong Liu
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is the curative treatment for Wiskott-Aldrich syndrome (WAS). However, it is difficult to find a matched donor for patients. Therefore, haploidentical donors should be considered for patients lacking a suitable donor. Our pilot study evaluated whether HSCT with posttransplantation cyclophosphamide (PTCy) is an effective treatment for WAS. METHODS: Haploidentical family donors were selected as donor sources for a total of five patients without a suitable donor between March 2015 and March 2017...
May 10, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29743403/-role-of-anti-ccr4-antibody-in-the-treatment-of-transplant-eligible-patients-with-aggressive-adult-t-cell-leukemia-lymphoma
#13
Shigeo Fuji
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell lymphoma caused by the human T-cell lymphotropic virus type I. Patients with aggressive ATL show dismal prognoses, even with intensive dose-dense chemotherapy. Such patients often show chemo-refractoriness. Mogamulizumab (Moga) is a potent treatment option for patients with relapsed or refractory ATL. However, use of Moga before allo-HSCT could theoretically increase the risk of post-transplant complications like graft-versus-host disease (GVHD) as Moga depletes regulatory T-cells (Tregs)...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29739773/graft-versus-host-disease-in-recipients-of-male-unrelated-donor-compared-with-parous-female-sibling-donor-transplants
#14
Anita J Kumar, Soyoung Kim, Michael T Hemmer, Mukta Arora, Stephen R Spellman, Joseph A Pidala, Daniel R Couriel, Amin M Alousi, Mahmoud D Aljurf, Jean-Yves Cahn, Mitchell S Cairo, Corey S Cutler, Shatha Farhan, Usama Gergis, Gregory A Hale, Shahrukh K Hashmi, Yoshihiro Inamoto, Rammurti T Kamble, Mohamed A Kharfan-Dabaja, Margaret L MacMillan, David I Marks, Hideki Nakasone, Maxim Norkin, Muna Qayed, Olle Ringden, Harry C Schouten, Kirk R Schultz, Melhem M Solh, Takanori Teshima, Alvaro Urbano-Ispizua, Leo F Verdonck, Robert Peter Gale, Betty K Hamilton, Navneet S Majhail, Alison W Loren
Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors...
May 8, 2018: Blood Advances
https://www.readbyqxmd.com/read/29734503/improved-survival-after-ltx-associated-acute-gvhd-with-mab-therapy-targeting-il2rab-and-soluble-tnfab-single-center-experience-and-systematic-review
#15
R C Minnee, S Fieuws, I Jochmans, R Aerts, M Sainz Barriga, Y Debaveye, J Maertens, P Vandenberghe, W Laleman, S van der Merwe, C Verslype, D Cassiman, P Ferdinande, F Nevens, J Pirenne, D Monbaliu
Acute graft-versus-host disease (GVHD) after liver transplantation (LTx) is a rare complication with a high mortality rate. Recently, monoclonal antibody (mAb) treatment, specifically with anti-interleukin-2 receptor antibody (IL2RAb) and anti-TNF-α antibody (TNFAb) gained increasing interest. However, evidence is mostly limited to case reports and the efficacy remains unclear. Here, we describe 5 patients with LTx-associated GVHD from our own center, and performed a systematic literature review to evaluate the potential therapeutic benefit of IL2RAb/TNFAb treatment...
May 7, 2018: American Journal of Transplantation
https://www.readbyqxmd.com/read/29728701/ibrutinib-for-bridging-to-allogeneic-hematopoietic-cell-transplantation-in-patients-with-chronic-lymphocytic-leukemia-or-mantle-cell-lymphoma-a-study-by-the-ebmt-chronic-malignancies-and-lymphoma-working-parties
#16
Peter Dreger, Mauricette Michallet, Paul Bosman, Sascha Dietrich, Mohamad Sobh, Ariane Boumendil, Arnon Nagler, Christof Scheid, Jan Cornelissen, Dietger Niederwieser, Lutz Müller, Elizabeth Vandenberghe, Ilaria Scortechini, Helene Schoemans, Niels S Andersen, Jürgen Finke, Domenico Russo, Per Ljungman, Jakob Passweg, Michel van Gelder, Nadira Durakovic, Helene Labussiere-Wallet, Tobias Berg, Gerald Wulf, Wolfgang Bethge, Donald Bunjes, Stefan Stilgenbauer, Maria Elisa Canepari, Michel Schaap, Christopher P Fox, Nicolaus Kröger, Silvia Montoto, Johannes Schetelig
The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients...
May 4, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29726580/hla-drb3-4-5-mismatches-are-associated-with-increased-risk-of-acute-gvhd-in-10-10-matched-unrelated-donor-hematopoietic-cell-transplantation
#17
Stéphanie Ducreux, Valérie Dubois, Kahina Amokrane, Ibrahim Yakoub-Agha, Myriam Labalette, Mauricette Michallet, Marie-Thérèse Rubio, Anne Kennel, Edouard Forcade, Xavier Lafarge, Claude-Eric Bulabois, Dominique Masson, Etienne Daguindau, Anne Devys, Virginie Moalic, Erwann Quelvennec, Abdelali Boudifa, Christophe Picard, Peter Van Endert, Muriel de Matteis, Florent Delbos, Matthieu Filloux, Béatrice Pedron, Virginie Renac, Françoise Hau, Julie Bonneau, Anne Parissiadis, Marylise Fort, Anne Dormoy, Natacha Maillard, Isabelle Jollet, Patrice Chevallier, Anne Cesbron, Jacques-Olivier Bay, Fabienne Quainon, Federico Garnier, Gérard Socié, Pascale Loiseau, Raphaël Porcher, Régis Peffault de Latour
Matching for HLA-A, -B, -C, and -DRB1 loci (8/8 match) is currently the gold standard for unrelated donor hematopoietic cell transplantation (HCT). In Europe, patients are also matched at the HLA-DQB1 loci (10/10 match). However, there is increasing evidence that matching at HLA-DRB3/4/5 loci may help to lower transplant-related morbidity and mortality. We therefore investigated the impact of HLA-DRB3/4/5 mismatches on outcomes in 1975 patients who received a first 10/10 matched unrelated donor (MUD) HCT in France from 2000 to 2012 for a hematological malignancy...
May 4, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29726078/unrelated-and-related-donor-transplantation-for-beta-thalassemia-major-a-single-center-experience-from-india
#18
M Joseph John, Amrith Mathew, Chepsy C Philip, Sohan Singh, Tanuja Tanuja, Naveen Kakkar
Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment in patients with β-thalassemia major. A matched sibling or a related donor is usually found in only 25%-30% of the patients. There are limited data on matched unrelated donor (MUD) transplants from India. We reviewed HSCT outcome in 56 children with TM who underwent 57 transplants at our center. Related donor (RD) (n=43) and MUD (n=14) transplants were performed with TreoFluT-based conditioning regimen in majority (95%) of patients...
May 3, 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29720575/prediction-of-acute-gvhd-and-relapse-by-metabolic-biomarkers-after-allogeneic-hematopoietic-stem-cell-transplantation
#19
Xiaojin Wu, Yiyu Xie, Chang Wang, Yue Han, Xiebing Bao, Shoubao Ma, Ahmet Yilmaz, Bingyu Yang, Yuhan Ji, Jinge Xu, Hong Liu, Suning Chen, Jianying Zhang, Jianhua Yu, Depei Wu
BACKGROUND: There are very few studies investigating metabolic biomarkers to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Metabolic models can provide a framework for analyzing the information-rich omics data sets in this setting. METHODS: Four hundred and fifty-six samples from one hundred and fourteen consecutive patients who underwent HSCT from January 2012 to May 2014 were collected for this study...
May 3, 2018: JCI Insight
https://www.readbyqxmd.com/read/29719098/allogeneic-hematopoietic-cell-transplant-following-crizotinib-monotherapy-for-relapsed-refractory-anaplastic-large-cell-lymphoma
#20
Tami D John, Swati Naik, Kathryn Leung, Ghadir Sasa, Caridad Martinez, Robert A Krance
Relapsed ALK-positive ALCL often is responsive to CRZ monotherapy. The subsequent role of allogeneic HCT after achieving second remission is poorly understood. We report 6 children who underwent allogeneic HCT for relapsed ALCL after CRZ. Age at transplant ranged from 10.7 to 22.6 years. Follow-up ranged from 0.9 to 4.5 years. All patients engrafted. Three of 4 patients that received a reduced-toxicity conditioning regimen containing fludarabine, alemtuzumab, and low-dose irradiation showed progressive mixed chimerism...
May 2, 2018: Pediatric Transplantation
keyword
keyword
59453
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"